Organic Active Ingredients TRIZ Cases

Thiazolopyridines selectively block A2A/A2B receptors, improving pharmacokinetics and reversing adenosine-driven T-cell inhibition.

Alumina purification removes impurities and standardizes hydroxypropyl beta-cyclodextrin for chronic intrathecal administration.

This case uses alcohol and an acid catalyst to lower 6-position acetylation while preserving water solubility and biodegradability.

Solubility enhancers, antioxidants, and pH control keep edaravone dissolved and stable for enteral administration.

This case converts Compound I into a crystalline salt for oral use, reducing thrombin formation and thrombus reformation during treatment.

This case uses tryptamine substitutions to preserve 5-HT2A modulation while reducing hallucinogenic effects and clinical dosing constraints.

This case uses salts and solid forms of an angiogenesis-control compound to improve stability and bioavailability while reducing side effects.

This case shows how rapamycin and related mTOR inhibitors may address Fuchs' dystrophy by reducing apoptosis and excess matrix.

This case varies cholesterol and ionizable lipid ratios to improve encapsulation while favoring liver over spleen expression.

This case combines HLA-A2/NY-ESO and CD3 binding with an Fc region to preserve antitumor targeting while extending antibody half-life.

This case uses THP-substituted bicyclic pyrimidinediones to modulate cardiac myosin, promote relaxation, and address HCM progression.

This case uses enantiomerically enriched 5-MAPB and 6-MAPB to shorten therapeutic onset while limiting abuse and toxic effects.

Selective M4 allosteric modulators target central activity while limiting peripheral side effects.

Controlled release maintains therapeutic diazoxide exposure while limiting peak-related effects in PWS and SMS treatment.

This case uses cyano-dimethyl-methyl isoxazoles and thiadiazoles to balance CB2 potency, CB1 selectivity, and low MDCK efflux.

This formulation uses defined ratios to promote beneficial gut bacteria, bowel regularity, tight junction proteins, and weight reduction.

This case uses circular ssDNA with homology arms to improve targeted insertion efficiency, specificity, and cell tolerance.

This case uses a thickener, controlled water activity, and low fat to carry high cannabinoid concentrations without undesirable flavor.

Omecamtiv mecarbil targets cardiac myosin to improve systolic function without the calcium-linked risks of traditional inotropes.

This case uses structurally varied tryptamine derivatives to modulate REM and non-REM sleep for dysregulated sleep conditions.

Cationic lipid particles shield nucleic acids from nucleases, while biodegradable groups support intracellular delivery and lipid removal.

This case develops thiazole derivatives that selectively inhibit TGFβR1, preserving normal TGFβ signaling for broader cancer treatment.

This case uses benzimidazole salts to protect sensory neurons and Schwann cells during chemotherapy-related peripheral neuropathy.

Lyophilize and store pharmaceuticals in one bag, then break the seal to reconstitute them with less healthcare worker exposure.

This case combines SIRPα-Fc phagocytosis activation with azacitidine to address treatment limits in higher-risk MDS and AML.

Ebastine and alprazolam combine to address insomnia and inflammation-related pathways.

This oral composition avoids adverse surfactant interactions while supporting mucosal barriers and periodontal disease prevention.

This case uses aerosolized psychedelic drugs and driving gases to support rapid absorption, remote activation, and precise dosing.

Modified-release coatings place nitrite quenchers in amine drug multiparticulates to keep nitrosamine impurities below 1 ppm.

A pharmaceutical-grade Toluidine blue O formulation and dual-chamber sprayer support stable, convenient oral lesion screening.

A modular Formula II/III reaction limits solvent residue while improving MCT4 inhibitor selectivity and scalable production.

A hemi-ethyl acetate crystalline form addresses poor aqueous solubility and hydrolysis risks for rapid IV delivery.

This case uses NaCDC polymorphs, solvates, and bilayer tablets to manage colon release and limit high local concentrations.

This case combines BPL1 with rapid, slow, and resistant carbohydrates to address metabolic changes linked to diabetes.

Monitor HBeAg, HBsAg, HBV DNA, liver enzymes, and resistance markers to assess progression and adjust therapy proactively.

Thermally destabilized dsRNA seed regions reduce off-target silencing while preserving efficacy.

Merging selective COX-2 inhibitors with paracetamol reduces side effects while maintaining rapid therapeutic efficacy.

Salbutamol targets beta-2 adrenergic receptors to reduce melanogenesis, addressing inadequate current therapies for scar hyperpigmentation.

Segmented esterification and coupling steps produce substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines using commercial reagents.

Segmented Formula I compounds inhibit Galectin-3, resolving specificity versus synthesis complexity.

Stereoselective reduction of protected ribonolactone to beta-lactol derivatives resolves yield and stereoselectivity trade-offs in purine nucleoside synthesis.

Cationic branched PEI complexes hydrophobic drugs in aqueous carriers, retaining active agents at the administration site to reduce systemic toxicity.

SCD1 polypeptide activates cytotoxic T cells to regress tumors in dogs and cats.

Agomelatine treats obsessive compulsive disorder by switching from serotonin reuptake inhibition to dual receptor action, avoiding side effects.

Hydrolysable low molecular weight cationic lipids reduce liver toxicity while maintaining siRNA delivery efficiency.

Segmented ligand drug conjugates deplete intracellular NAD+ in cancer cells while sparing normal tissue cytotoxicity.

Rapamycin derivatives inhibit mTOR signaling to regress tumors, replacing invasive surgery and reducing morbidity in tuberous sclerosis treatment.

Partial agonists activate NLRP3 to enhance therapeutic efficacy in cancer while minimizing adverse effects from full receptor activation.

A semipermeable epithelial membrane graft placed in the skull base enables targeted pharmaceutical delivery to the central nervous system.

Combining toremifene with melatonin targets SARS-CoV-2 spike protein interactions while reducing inflammation.

A phosphoramidate compound releases cytotoxic aziridine via AKR1C3 enzyme activation.

Incorporating cholesterol at 0.05% to 15% mitigates oxybutynin-induced skin irritation without compromising transdermal absorption reliability.

Cannabinoid receptor 1 antagonists combined with microRNA inhibitors reduce pro-inflammatory cytokine secretion in adipose tissue.

Random decision forests process social media content features combined with subjective polling to automate talent identification.

Heated resin flows into segmented cavities to form uniform shells, resolving dispensing accuracy issues.

S-equol activates estrogen receptor beta to suppress tumor growth while reducing chemotherapy toxicity in triple-negative breast cancer.

Modified benzothiazole structures reduce platelet toxicity and improve water solubility for safer Bcl-xL inhibition.

PROTAC molecules degrade ER, AR, and BRD proteins via E3 ligase recruitment, overcoming resistance and side effects of direct inhibitors.

DMTMM crosslinks collagen-like peptides into hydrogels that solve donor tissue shortages while maintaining vision restoration reliability.

Modified oligonucleotides resolve stability and efficacy trade-offs by forming irreversible duplexes that lower required dosages.

TM4SF5-peptide-equipped extracellular vesicles transport miR143 to colon cancer cells, reducing side effects from non-specific drug distribution.

Topical pharmaceutical bases containing pracaxi oil and breu-branco resin reduce API dosage requirements while treating keloids and hypertrophic scars.

Dual inhibition of SOS1 and KRAS G12C shifts equilibrium to inactive KRAS, delaying resistance for durable anticancer responses.

Targeting folate and one-carbon metabolism pathways with specific inhibitors reduces viral replication while minimizing host cell toxicity.

Cysteine prodrugs mediate active moiety transport across the blood-brain barrier, reducing systemic toxicity while maintaining therapeutic efficacy.

Trans sodium crocetinate enhances oxygen diffusion to treat hypoxemia, reducing mechanical ventilation needs and mortality.

Segmenting the drug into a freeze-dried powder and reconstitution solution overcomes poor water solubility while maintaining long-term storage stability.

Therapeutic GC molecule composition reduces SARS-CoV-2 virus titers by more than 15-fold through direct antiviral action.

Tranilast upregulates miR-29c and miR-200c, reducing promoter methylation to treat uterine leiomyoma without side effects.

Conjugated vitamin C derivatives extend bioavailability in hyaluronic acid dermal fillers.

Adjusting pH to 6.3-7.3 prevents precipitation and hydrolysis in aqueous ibuprofen and paracetamol formulations.

Novel bicyclic heterocyclic compound inhibits KAT-II to reduce brain KYNA levels for treating schizophrenia.

Combines CDK inhibitor RO-3306 with ID2 activator apigenin to induce apoptosis and suppress invasiveness, addressing high recurrence rates.

An aptamer binds lead ions through affinity interactions to prevent absorption and eliminate toxins from the body.

Reductive amination couples doxorubicin to hydroxybisphosphonic acid, resolving the trade-off between bone targeting affinity and aqueous solubility.

A hyaluronic acid and laminin polypeptide hydrogel implanted after the acute phase prevents glial scarring to enable axonal growth in chronic nerve injuries.

N,N'-(5,5'-bis(1,3,4-thiadiazole))bis(2-(pyridin-2-yl)acetamide) inhibits glutaminase activity to reduce intracellular glutathione levels in cancer cells.

Modified mu-opioid receptor agonists treat Huntington's disease and Rett syndrome while reducing respiratory depression and addiction risks.

Halogenated compounds treat comorbid anxiety and depression disorders while avoiding the withdrawal syndrome risk associated with conventional antidepressants.

Rhodium-catalyzed asymmetric synthesis produces enantiomerically pure compounds that overcome tumor cell resistance while minimizing side effects.

Dextrose-based peritoneal dialysis infusates remove sodium and fluid while maintaining stable serum levels to prevent disequilibrium syndrome.

Modified chemical scaffolds provide broad-spectrum activity against all three main infective species while maintaining efficacy against juvenile worms.

Pyrazolo[1,5-a]pyrimidine compounds selectively inhibit Trk kinases to treat pain and cancer while avoiding opioid addiction and NSAID ulcers.

A polymalic acid nanoconjugate delivers temozolomide via receptor-mediated endocytosis and pH-dependent endosomal escape.

Aptamer molecules bind viral spike glycoproteins to block infection while neutralizing autoantibodies linked to long COVID symptoms.

Oxazolidinone pyrimidine compounds inhibit multiple PI3K isoforms while avoiding mTOR and tubulin off-target toxicity.

5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives inhibit MET receptor tyrosine kinase activity.

Photo-crosslinked bioreducible polymeric nanoparticles encapsulate siRNA with disulfide bonds, resolving serum stability and cellular uptake trade-offs.

Cytokine receptor agents activate NK cells to eliminate senescent cells, resolving the selectivity and safety trade-off in aging treatments.

Mineralocorticoid receptor antagonists reduce vascular leakage and CNV size, addressing anti-VEGF therapy resistance.

Specific concentration ranges of lactic acid and hydrogen peroxide in the gel treat infections by lowering vaginal pH.

Peptide compounds interact with ion channels to reduce hyperalgesia and allodynia, avoiding side effects of traditional antiepileptic drugs.

Novel 4-carbonylamino-4-phenylpyrimidine compound activates glutamate dehydrogenase to regulate liver energy metabolism.

Aerosolizable material formulation maintains low turbidity through precise carrier constituent ratios.

Novel compounds act as CGRP receptor antagonists via subcutaneous or intranasal routes, avoiding liver toxicity caused by oral first-pass metabolism.

C5-substituted carbapenem antibiotics target mycobacterial transpeptidase to reduce microbiome disruption while maintaining efficacy.